Unknown

Dataset Information

0

Interspinous Process Decompression Improves Quality of Life in Patients with Lumbar Spinal Stenosis.


ABSTRACT: Lumbar spinal stenosis has been shown to negatively impact health-related quality of life. Interspinous process decompression (IPD) is a minimally invasive procedure that utilizes a stand-alone spacer to serve as a joint extension blocker to relieve neural compression in patients with spinal stenosis. Using the 5-year results from an FDA randomized controlled trial of IPD, the quality of life in 189 patients treated with the Superion® spacer was evaluated with the SF-12. Physical and mental component summary (PCS, MCS) scores were computed preoperatively and at annual intervals. For the PCS, mean scores improved from 29.4 ± 8.1 preoperatively to 41.2 ± 12.4 at 2 years (40%) and to 43.8 ± 11.6 at 5 years (49%) (p<0.001 for both comparisons). At 2 years, 81% (103 of 128) of subjects demonstrated maintenance or improvement in PCS scores. The mean MCS score improved from 50.0 ± 12.7 preoperatively to 54.4 ± 10.6 and 54.7 ± 8.6 at 2 and 5 years, respectively (p>0.10 for both comparisons). These results demonstrate that the significant impairment in physical well-being found in patients with lumbar spinal stenosis can be ameliorated, in large part, by IPD treatment.

SUBMITTER: Nunley PD 

PROVIDER: S-EPMC6051048 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Interspinous Process Decompression Improves Quality of Life in Patients with Lumbar Spinal Stenosis.

Nunley Pierce D PD   Patel Vikas V VV   Orndorff Douglas G DG   Lavelle William F WF   Block Jon E JE   Geisler Fred H FH  

Minimally invasive surgery 20180702


Lumbar spinal stenosis has been shown to negatively impact health-related quality of life. Interspinous process decompression (IPD) is a minimally invasive procedure that utilizes a stand-alone spacer to serve as a joint extension blocker to relieve neural compression in patients with spinal stenosis. Using the 5-year results from an FDA randomized controlled trial of IPD, the quality of life in 189 patients treated with the Superion® spacer was evaluated with the SF-12. Physical and mental comp  ...[more]

Similar Datasets

| S-EPMC5593396 | biostudies-literature
| S-EPMC6251434 | biostudies-literature
| S-EPMC3898636 | biostudies-literature
| S-EPMC3427972 | biostudies-other
| S-EPMC6106718 | biostudies-literature
| S-EPMC3289933 | biostudies-literature
| S-EPMC8550110 | biostudies-literature
| S-EPMC11373059 | biostudies-literature
| S-EPMC7429717 | biostudies-literature
| S-EPMC10409656 | biostudies-literature